Index Entries

Emilia Cirillo, Ciro Esposito, Giuliana Giardino, Gaetano Azan, Simona Fecarotta, Stefania Pittaluga, Lucia Ruggiero, Ferdinando Barretta, Giulia Frisso, Luigi Daniele Notarangelo, and Claudio Pignata
March 16, 2022
Frontiers in Immunology
Federico II University of Naples (Italy)

"Case Report

The patient was a previously healthy 68-year-old man, with no risk factors, who received the first dose of ChAdOx1 nCov-19 vaccine on April 19, 2021...

Discussion

Here, we report on a case of fatal rhabdomyolysis that occurred 9 days after vaccination for ChAdOx1 nCov-19, complicated by a multiorgan failure involving bone marrow, liver, kidney, and lung in a previously healthy subject... 

ChAdOx1 nCoV-19 is a SARS-CoV-2 vaccine comprising a replication-deficient simian adenovirus expressing full-length SARS-CoV-2 spike protein. Side effects associated to ChAdOx1 nCov-19 are usually mild and self-limiting. Venous thrombo-embolism in unusual sites with a fatal outcome has been occasionally reported. Following vaccinations, a few cases of rhabdomyiolysis in patients receiving influenza, varicella zoster and, more recently, also following mRNA vaccination, have been documented...

In conclusion, even though the pathophysiology of muscle injury in the patient herein described has not been clearly established, a possible explanation is that an exaggerated immune response to the ChAdOx1 nCoV-19 vaccine induced severe rhabdomyolysis in a patient with a genetic risk factor. Given the temporal association with the vaccination, monitoring for the possible occurrence of similar cases is recommended."

document
adverse events,clinical cases,COVID-19,deaths,vaccines